214917-68-7

Basic information

• Product Name: 2,6-Difluoro-4-hydroxybenzoic acid
• Synonyms: RARECHEM AL BO 2259;2,6-DIFLUORO-4-HYDROXYBENZOIC ACID;2,6-Difluoro-4-hydroxylbenzoic acid;4-Carboxy-3,5-difluorophenol;Benzoic acid, 2,6-difluoro-4-hydroxy-
• CAS NO: 214917-68-7
• Molecular Formula: C7H4F2O3
• Molecular Weight: 174.1
• EINECS: 1592732-453-0
• Product Categories: Aromatic Carboxylic Acids, Amides, Anilides, Anhydrides & Salts
• Mol File: 214917-68-7.mol
• Article Data: 7

Chemical Properties

• Melting Point: 170-171°C
• Boiling Point: 323.3 °C at 760 mmHg
• Flash Point: 149.3 °C
• Appearance: /
• Density: 1.6 g/cm³
• Vapor Pressure: 0.000109mmHg at 25°C
• Refractive Index: 1.557
• Storage Temp.: Sealed in dry,Room Temperature
• Solubility: soluble in Methanol
• PKA: 2.71±0.10(Predicted)
• CAS DataBase Reference: 2,6-Difluoro-4-hydroxybenzoic acid(CAS DataBase Reference)
• NIST Chemistry Reference: 2,6-Difluoro-4-hydroxybenzoic acid(214917-68-7)
• EPA Substance Registry System: 2,6-Difluoro-4-hydroxybenzoic acid(214917-68-7)

Safety Data

• Hazard Codes: Xi
• Hazardous Substances Data: 214917-68-7(Hazardous Substances Data)

Usage

Uses

2,6-Difluoro-4-hydroxybenzoic Acid is a fluorobenzoic acid derivative and a synthetic intermediate in the synthesis of various pharmaceutical goods.

InChI:InChI=1/C7H4F2O3/c8-4-1-3(10)2-5(9)6(4)7(11)12/h1-2,10H,(H,11,12)

Upstream product

• 123843-57-2 2,6-difluoro-4-hydroxybenzonitrile 
• 2713-34-0 3,5-difluorophenol 
• 124-38-9 carbon dioxide 
• 749230-20-4 1,3-difluoro-5-(methoxymethoxy)benzene 
• 28314-80-9 2,4,6-trifluorobenzoic acid 

Downstream Products

• 123843-56-1 4-butoxy-2,6-difluorobenzoic acid 
• 916483-56-2 4-ethoxy-2,6-difluorobenzoic acid 
• 1393900-16-7 C₁₂H₁₄F₂O₃ 
• 1393900-15-6 C₁₀H₁₀F₂O₃ 
• 1472068-02-2 4-[(2,6-difluoro-4-hydroxybenzyl)(4H-1,2,4-triazol-4-yl)amino]-benzonitrile 

Relevant articles and documents

TARGETED PROTEIN DEGRADATION OF PARP14 FOR USE IN THERAPY

The present invention relates to quinazolinones and related compounds which degrade PARP14 and are useful, for example, in the treatment of cancer and inflammatory diseases.

Topical Intestinal Aminoimidazole Agonists of G-Protein-Coupled Bile Acid Receptor 1 Promote Glucagon Like Peptide-1 Secretion and Improve Glucose Tolerance

The role of the G-protein-coupled bile acid receptor TGR5 in various organs, tissues, and cell types, specifically in intestinal endocrine L-cells and brown adipose tissue, has made it a promising therapeutical target in several diseases, especially type-2 diabetes and metabolic syndrome. However, recent studies have shown deleterious on-target effects of systemic TGR5 agonists. To avoid these systemic effects while stimulating glucagon-like peptide-1 (GLP-1) secreting enteroendocrine L-cells, we have designed TGR5 agonists with low intestinal permeability. In this article, we describe their synthesis, characterization, and biological evaluation. Among them, compound 24 is a potent GLP-1 secretagogue, has low effect on gallbladder volume, and improves glucose homeostasis in a preclinical murine model of diet-induced obesity and insulin resistance, making the proof of concept of the potential of topical intestinal TGR5 agonists as therapeutic agents in type-2 diabetes.

Synthesis and mesomorphic properties of two series of laterally fluorinated symmetric ester liquid crystals

Two series of symmetric ester liquid crystals (nAFBHQ and nADFBHQ) with lateral fluorine atoms have been synthesized. Their chemical structures were measured by FTIR, 1H NMR, and elemental analysis (EA). Their mesomorphic properties were investigated by d